Biotrial has completed its acquisition of Warnex Bioanalytical Services Division and has launched BBS, Biotrial Bioanalytical Services. The acquisition expands Biotrial’s drug development services to international clients, providing access to the full spectrum of bioanalytical services to support preclinical and clinical development, including generics product development.
The acquisition brings a team of experts including a staff of more than 70, more than 250 validated assays, and 25,000-sq.-ft. labs. BBS services have SCC certification and have been audited by the FDA and AGES regulatory agencies. Services include: method development and validation, preclinical, bioavailability and bioequivalence studies, as well as therapeutic drug monitoring.
Jean-Marc Gandon, P. Pharm., president and chief executive officer of Biotrial, said, “We have been looking for many years to find the right partner to complement our offer with sample analysis so that our customers could benefit from a full package in their process of developing new drugs or generics. Biotrial is committed to continue providing the excellent service and quality of science for which the Montreal site is known for, by continuing its investment in the latest state-of-the-art equipment.”
Michael Mancini, Ph.D., BBS’ president, said, “It has been a very smooth transition and we are particularly excited to officially be a part of the Biotrial team. There is no change in management or staff and for us it is ‘business as usual.’ Being a part of such an international and well recognized CRO ensures that we will continue to expand our service offering as we have been doing for so many years.”